WHO recognizes for the first time that "single-dose" HPV vaccination can effectively prevent cervical cancer The stock prices of


  three domestic HPV vaccine listed companies plummeted

  On April 14, bad news about HPV suddenly came out of the market: the World Health Organization (WHO) approved the "single-dose" HPV vaccination program for the first time.

Affected by this, Zhifei Bio, Wantai Bio and Watson Bio all dived.

Among them, Zhifei Bio fell the most by more than 18%, Watson Bio once fell by more than 7%, and Wantai Bio fell by the intraday limit.

Yesterday noon, the above-mentioned companies also responded to the matter urgently.

  WHO certified

  single dose

  Equivalent to multiple effects

  A reporter from Beijing Youth Daily learned that the World Health Organization (WHO) announced on its official website that the organization held a meeting of the Strategic Expert Group on Immunization (SAGE) from April 4 to 7. ) vaccination evidence was reviewed.

CONCLUSIONS: A single-dose HPV vaccination regimen can effectively prevent cervical cancer caused by persistent HPV infection, and is equivalent to a two-dose or three-dose regimen.

  Up to now, there are 5 HPV vaccines approved and marketed in the world, namely GlaxoSmithKline's bivalent HPV vaccine, Merck's quadrivalent HPV and nine-valent HPV vaccine, Wantai Bio's bivalent HPV vaccine and Watson Bio II The latter two companies are Chinese companies.

And Merck's HPV vaccine Jiadaxiu is exclusively represented by Zhifei Biological in China.

  In my country, these five vaccines have all been approved for marketing, and they are basically two-dose and three-dose forms, and there is no single-dose vaccination yet.

  Changes in the market

  Shares of three domestic related companies plummeted

  The news of WHO was regarded as bad news by the market, which directly caused the stock prices of three related listed companies to plummet.

On April 14, less than an hour after the opening of Zhifei Bio, the stock price continued to fall, falling more than 18% within half an hour, and the decline narrowed to 10% in the afternoon.

Wantai Bio reached the lower limit half an hour after the opening, and opened the lower limit in the afternoon.

Watson Bio’s stock price turned red for a while in the morning, but it still fell by more than 7%, and the decline narrowed to 2% in the afternoon.

  In response to this news, the staff of Zhifei Bio's board secretary office said that all operations within the company were normal, and the sharp drop in the stock price was mainly due to the news released by the WHO. It was indeed mentioned that three shots of HPV vaccine can only be given one shot, but No clinical data support is given, and the company is also discussing to actively respond to this situation.

  Wantai Bio issued a statement at noon on the 14th, stating that the company's currently approved bivalent HPV vaccine in China is 3 doses (2 doses for women aged 9-14).

Under the current national drug administration policy, if the dose of vaccination is changed, a series of clinical, data support and registration change procedures need to be performed. Before the change of the national policy, the company will continue to sell according to the currently approved dose.

  Watson Bio's bivalent HPV vaccine is not yet on the market.

The vaccine just received drug approval in March this year.

At the performance briefing on April 6, Zhang Li, secretary of Watson Bio’s board of directors, said that the company’s bivalent HPV vaccine is expected to be released in batches in the second quarter, and the access work has been carried out in various provinces and cities in China.

  Industry Analysis

  "Bad news" may be misreading

  Some people in the industry believe that if there is a situation where 3 doses are reduced to 1 dose, the revenue of related companies may be greatly affected.

However, there are also many brokerage research institutions that believe that this is a misunderstanding of WHO's information by the market.

Debon Securities believes that the fundamental reason for the WHO's review of the clinical effects of single-dose HPV vaccines is that HPV vaccines are still in a state of shortage of production capacity in the world. After understanding this background, the trend of exporting domestic HPV vaccines will be very clear. .

  The Beijing Youth Daily reporter learned that the WHO said that by 2020, the global coverage of the three-dose HPV vaccine will only be 13%.

Behind the slow rate of HPV vaccination and low coverage, it is also constrained by factors such as insufficient supply and high vaccination costs.

As early as November 2020, WHO has released the "Global Strategy to Accelerate the Elimination of Cervical Cancer", one of the goals is that by 2030, 90% of girls have completed HPV vaccination before the age of 15.

  WHO Assistant Director-General Nothemba Simelela currently believes that the single-dose HPV vaccination recommendation has the potential to drive this goal faster, while at the same time, single-dose vaccination is less costly and less resource-intensive, saving health money and manpower Resources can be used for other health priorities.

  Huaxi Securities believes that domestic vaccination procedures and clinical programs have extremely strict regulations and requirements. It is impossible to revise the vaccination program based on the results of an informal meeting.

Text / reporter Zhang Xin

Keywords: